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CorrespondenceIn the last ten years, the impor-
tance of chromatin modifications 
in many aspects of biology has 
become apparent. Several families 
of enzymes that modify histones 
have been identified, the majority 
of which are conserved throughout 
evolution. The enormous interest in 
this field has resulted in a very rapid 
rate of discovery of new enzymes, 
but this in turn has lead to a nonco-
herent nomenclature that is incon-
sistent between species and often 
confusing to the many scientists 
who use them.
A number of scientists feel that this 
situation needs to be rectified, not 
only for those currently working with 
these enzymes but also for future 
generations of young scientists who 
are interested in joining the field. We 
therefore propose to rationalize the 
nomenclature for some of the most 
inconsistently named families of 
chromatin-modifying enzymes.
Here, we propose a new nomencla-
ture for all the characterized members 
of the families of lysine demethylases, 
acetyltransferases,  and lysine methyl-
transferases. Many of these enzymes 
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as substrates but were subsequently 
shown to target nonhistone proteins. 
Therefore, these enzymes have been 
given a more generic name that reflects 
(1) the type of enzymatic activity they 
perform and (2) the type of residue they 
modify. Thus, lysine demethylases will 
become KDMs (K-demethylases; Table 
1), acetyltransferases will become KATs 
(K-acetyltransferases; Table 2), and 
lysine methyltransferases will become 
KMTs (K-methyltransferases; Table 3).
In the three tables that follow, we 
have renamed the three families of 
enzymes according to the following 
guidelines.
Relationships
The first consideration in naming simi-
lar enzymes was their close relation-
ship in sequence and domain structure/
organization, including the catalytic Table 1. K-Demethylases (KDMs; Formerly Lysine Demethylases)
New Name Human D. melanogaster S. cerevisiae S. pombe
Substrate 
 Specificity Function
KDM1 LSD1/BHC110 Su(var)3-3 SpLsd1/Swm1/
Saf110
H3K4me1/2, 
H3K9me1/2 
Transcription activation 
and repression,  hetero-
chromatin formation
KDM2 Jhd1 H3K36me1/2 Transcription elongation
KDM2A JHDM1a/FBXL11 H3K36me1/2
KDM2B JHDM1b/FBXL10 H3K36me1/2
KDM3A JHDM2a H3K9me1/2 Androgen receptor gene ac-
tivation, spermatogenesis
KDM3B JHDM2b H3K9me
KDM4 Rph1 H3K9/
K36me2/3
Transcription elongation
KDM4A JMJD2A/JHDM3A H3K9/
K36me2/3
Transcription repression, 
genome integrity 
KDM4B JMJD2B H3K9/
H3K36me2/3
Heterochromatin  formation
KDM4C JMJD2C/GASC1 H3K9/
K36me2/3
Putative oncogene
KDM4D JMJD2D H3K9me2/3
KDM5 Lid Jhd2 Jmj2 H3K4me2/3
KDM5A JARID1A/RBP2 H3K4me2/3 Retinoblastoma- interacting 
protein
KDM5B JARID1B/PLU-1 H3K4me1/2/3 Transcription repression
KDM5C JARID1C/SMCX H3K4me2/3 X-linked mental  retardation
KDM5D JARID1D/SMCY H3K4me2/3 Male-specific antigen
KDM6A UTX H3K27me2/3 Transcription activation
KDM6B JMJD3 H3K27me2/3 Transcription activationember 16, 2007 ©2007 Elsevier Inc. 633
Table 2. K-Acetyltransferases (KATs; Formerly Acetyltransferases) 
New Name Human D. melanogaster S. cerevisiae S. pombe Substrate Specificity Function
KAT1 HAT1 CG2051 Hat1 Hat1/
Hag603
H4 (5, 12) Histone deposition, DNA 
repair
KAT2 dGCN5/PCAF Gcn5 Gcn5 H3 (9, 14, 18, 23, 36)/
H2B; yHtzl (14)
Transcription activation, 
DNA repair
KAT2A hGCN5 H3 (9, 14, 18)/H2B Transcription activation
KAT2B PCAF H3 (9, 14, 18)/H2B Transcription activation
KAT3 dCBP/NEJ H4 (5, 8); H3 (14, 18) Transcription activation, 
DNA repair
KAT3A CBP H2A (5); H2B (12, 15) Transcription activation
KAT3B P300 H2A (5); H2B (12, 15) Transcription activation
KAT4 TAF1 dTAF1 Taf1 Taf1 H3 > H4 Transcription activation
KAT5 TIP60/PLIP dTIP60 Esa1 Mst1 H4 (5, 8, 12, 16); H2A 
(yeast 4, 7; chicken 5, 9, 
13, 15); dH2Av/yHtzl  
(14)
Transcription activation, 
DNA repair
KAT6 (CG1894) Sas3 (Mst2) H3 (14, 23) Transcription activation 
and elongation, DNA 
replication
KAT6A MOZ/MYST3 ENOK H3 (14) Transcription activation
KAT6B MORF/MYST4 H3 (14) Transcription activation
KAT7 HBO1/MYST2 CHM (Mst2) H4 (5, 8, 12) > H3 Transcription, DNA 
 replication
KAT8 HMOF/MYST1 dMOF (CG1894) Sas2 (Mst2) H4 (16) Chromatin boundaries, 
dosage compensation, 
DNA repair
KAT9 ELP3 dELP3/ 
CG15433
Elp3 Elp3 H3
KAT10 Hap2 H3 (14); H4
KAT11 Rtt109 H3 (56) Genome stability, 
 transcription elongation
KAT12 TFIIIC90 H3 (9, 14, 18) Pol III transcription
KAT13A SRC1 H3/H4 Transcription activation
KAT13B ACTR H3/H4 Transcription activation
KAT13C P160 H3/H4 Transcription activation
KAT13D CLOCK H3/H4 Transcription activationdomain. The domain structure may not 
extend across the entire protein, but it 
should be clearly recognizable as evo-
lutionarily related. The second consid-
eration (if the domain structure is not 
recognizable) was sequence homology 
between enzyme catalytic domains 
and, if necessary, their substrate spec-
ificity. Thus, related enzymes from a 
single species have been given the 
same name but with a capital letter as a 
distinguishing suffix (e.g., A or B). Simi-
lar enzymes in different species have 
been given an identical name but with 
a different prefix to denote species of 634 Cell 131, November 16, 2007 ©2007origin (e.g., h = human, d = Drosophila, 
Sc = Saccharomyces cerevisiae, Sp = 
S. pombe). As an example, the human 
demethylase LSD1/BHC110 would 
become hKDM1, the Drosophila equiv-
alent Su(var)3-3 would be dKDM1, and 
the fission yeast equivalent SpLsd1/
Swm1/Saf110 would be SpKDM1.
Numbering
The first three numbers were 
assigned according to the order of 
discovery (regardless of species), 
and more specifically in the order 
of the published reports of enzy- Elsevier Inc.matic activity. Following the first 
three numbers, numbers were then 
assigned as far as possible in order 
of published reports.
Enzymes to be Renamed
Characterized enzymes from each 
family that have been shown to tar-
get histones have been renamed. In 
the future, if another family member is 
described to have activity, the above 
rules should be used to name it and 
to give it the next appropriate num-
ber and/or suffix. In the current list, 
we have presented yeast, Drosophila, 
Table 3. K-Methyltransferases (KMTs; Formerly Lysine Methyltransferases)
New Name Human D. melanogaster S. cerevisiae S. pombe
Substrate 
Specificity Function
KMT1 Su(Var)3-9 Clr4 H3K9 Heterochromatin  
formation/silencing
KMT1A SUV39H1 H3K9 Heterochromatin  
formation/silencing
KMT1B SUV39H2 H3K9 Heterochromatin  
formation/silencing
KMT1C G9a H3K9 Heterochromatin  
formation/silencing
KMT1D EuHMTase/GLP H3K9 Heterochromatin  
formation/silencing
KMT1E ESET/SETDB1 H3K9 Transcription repression
KMT1F CLL8
KMT2 Set1 Set1 H3K4 Transcription activation
KMT2A MLL1 Trx H3K4 Transcription activation
KMT2B MLL2 Trx H3K4 Transcription activation
KMT2C MLL3 Trr H3K4 Transcription activation
KMT2D MLL4 Trr H3K4 Transcription activation
KMT2E MLL5 H3K4 Transcription activation
KMT2F hSET1A H3K4 Transcription activation
KMT2G hSET1B H3K4 Transcription activation
KMT2H ASH1 Ash1 H3K4 Transcription activation
KMT3 Set2 Set2 H3K36 Transcription activation
KMT3A SET2 H3K36 Transcription activation
KMT3B NSD1 H3K36
KMT3C SYMD2 H3K36 (p53) Transcription activation
KMT4 DOT1L Dot1 H3K79 Transcription activation
KMT5 Set9 H4K20 DNA-damage response
KMT5A Pr-SET7/8 PR-set7 H4K20 Transcription repression
KMT5B SUV4-20H1 Suv4-20 H4K20 DNA-damage response
KMT5C SUV4-20H2
KMT6 EZH2 E(Z) H3K27 Polycomb silencing
KMT7 SET7/9 H3K4 (p53 and 
TAF10)
KMT8 RIZ1 H3K9 Transcription repressionand human enzymes as these repre-
sent well-studied yet diverse points 
on the evolutionary scale. We recog-
nize that this list is only partially com-
plete and therefore urge colleagues 
working with other organisms to use 
the above guidelines to rationalize 
the enzymes in their particular organ-
isms. We are hoping that any exten-
sion of the lists presented here may 
be done in a more coherent fashion 
once a widely accessible database of 
enzymes is set up.At the present time, the new 
names are given to the protein and 
not the gene for a particular enzyme. 
Renaming the gene requires official 
permission, which we may seek in 
the future, if necessary. We have not 
suggested renaming the HDAC and 
PRMT families. We felt that each of 
these families already has a coher-
ent nomenclature and that renaming 
them may serve to confuse rather 
than clarify. There are indeed other 
enzymatic activities that modify his-Cell 131, Novetones that we have not attempted 
to rename according to these new 
rules. This can easily be done in due 
course using the above guidelines.
We sincerely hope that this new 
nomenclature will help to unify the 
field. We expect that in the short 
term, these enzymes will be referred 
to by their new and old names in 
order to facilitate transition to the 
new terminology (see SnapShot of 
new nomenclature, last page of this 
issue).mber 16, 2007 ©2007 Elsevier Inc. 635
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